Korea United Pharm (CEO Kang Deok-young) acquired a license for the item’Atromac Combigel Soft Capsule’, an improved new drug combination drug on the 21st.
The superiority of the treatment effect (non-HDL-C change rate) compared to the administration of atorvastatin alone was demonstrated through phase 3 clinical trials of Atromac Combigel soft capsule. Atorvastatin alone therapy is expected to be a new treatment option for patients with complex dyslipidemia in which low-density lipoprotein-cholesterol (LDL-C) is properly controlled but triglyceride levels are not controlled.
Korea United Pharm’s Atromac Combigel soft capsule is a formulation containing omega-3 fatty acid esters and atorvastatin (Omega-3-acid ethylester and Atrovastatin).’CombiGel’ technology Technology) applied. A tablet containing a statin drug, a treatment for hyperlipidemia, was inserted into the soft capsule. You can also visually check the form of the pill in the capsule.
Atrophic Combigel soft capsules were developed based on the fact that omega-3 fatty acid esters and atorvastatin are often prescribed in combination. Omega-3 fatty acid esters are administered in combination with statin drugs to patients with a combination of hypercholesterolemia and hypertriglyceridemia whose triglyceride levels are not controlled.
In fact, about 40% of patients prescribed omega-3 fatty acid esters are taking statin drugs together. Since about half of them are prescribed atorvastatin, they are expected to secure a high market share in the dyslipidemia market.
Currently, two formulation patents and one manufacturing facility patent related to Atromac Combigel soft capsules are registered in Korea. Two domestically registered formulation patents are related to formulation technology that puts tablets in soft capsules, and by blocking external contact such as moisture and air, compared to existing formulations, it is possible to secure high drug stability by preventing a decrease in drug content.
Recently, patents registered in Japan and Vietnam were also patented in recognition of the advancement in the formulation technology and drug stability effect of soft capsules, and the exclusive rights of drug-related technologies were guaranteed in Japan by 2037 and Vietnam by 2035. It has also been applied for and is being examined in the US, China, Europe, Thailand, and the Philippines.
Atorvastatin and Omega-3 are each forming a market of 560 billion won and 80 billion won per year (as of UBIST 2020). It is known that a number of companies developed the combination prescription due to frequent prescriptions. Hankook United Pharm is expected to take a high market share by preoccupying the market when the product is released by successfully developing it for the first time in Korea.
CEO Kang Deok-young said, “Atromac Combigel Soft Capsule is the first combination of atorvastatin and omega-3 in Korea, and it is expected to contribute to chronic disease management by facilitating prescriptions by medical staff and by patients.” “The formulation technology. It is expected to exert a great influence in the market as a product produced through thorough preparation and R&D, such as in-house facilities and patent acquisition.”